Organon & Co
NYSE : OGN$13.76+0.00%Oct 16 close
Financials
Condensed Consolidated Statements of Income
USD · reported units. Click a value to inspect its source.
| Reported line item | Apr 1, 2026 to Jun 30, 2026 (current) | Jan 1, 2026 to Jun 30, 2026 | Apr 1, 2025 to Jun 30, 2025 | Jan 1, 2025 to Jun 30, 2025 |
|---|---|---|---|---|
| Income Statement [Abstract] | ||||
| Revenues | ||||
| Cost of sales | ||||
| Gross profit | ||||
| Selling, general and administrative | ||||
| Research and development | ||||
| Acquired in-process research and development and milestones | ||||
| Restructuring costs | ||||
| Interest expense | ||||
| Exchange losses (gains) | ||||
| Other expense (income), net | ||||
| Income before income taxes | ||||
| Income tax expense | ||||
| Net income | ||||
| Earnings per share: | ||||
| Basic (in dollars per share)USD / share | ||||
| Diluted (in dollars per share)USD / share | ||||
| Weighted average shares outstanding: | ||||
| Basic (in shares)Shares | ||||
| Diluted (in shares)Shares |
17 line items · 4 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.